NewLink Genetics Corporation (NLNK) - NASDAQ
  • Yesterday, 8:02 AM
    • NewLink Genetics (NASDAQ:NLNK): Q2 EPS of -$1.12 misses by $0.35.
    • Revenue of $2.01M (-73.0% Y/Y) misses by $3.4M.
    • Press Release
    | Yesterday, 8:02 AM | 1 Comment
  • Fri, Apr. 29, 10:00 AM
    • NewLink Genetics (NLNK +6.2%) Q1 results: Revenues: $5.7M (-85.5%); R&D Expense: $21.9M (+21.7%); SG&A: $9.2M (+9.5%); Operating Loss: ($25.4M) (-298.4%); Net Loss: ($23.7M) (-311.6%); Loss Per Share: ($0.82) (-334.3%); Quick Assets: $178M (-10.0%).
    • No guidance given.
    | Fri, Apr. 29, 10:00 AM | 1 Comment
  • Fri, Apr. 29, 8:04 AM
    • NewLink Genetics (NASDAQ:NLNK): Q1 EPS of -$0.82 beats by $0.88.
    • Revenue of $5.71M (-85.4% Y/Y) beats by $3.63M.
    • Press Release
    | Fri, Apr. 29, 8:04 AM | 6 Comments
  • Mon, Feb. 29, 10:05 AM
    • NewLink Genetics (NLNK +5.5%) Q4 results: Revenues: $7.7M (-95.4%); R&D Expense: $14.8M (+24.4%); SG&A: $7.7M (-7.2%); Operating Loss: ($14.8M) (-109.9%); Net Loss: ($21.6M) (-118.0%); Loss Per Share: ($0.75) (-119.6%).
    • FY2015 results: Revenues: $68.5M (-60.3%); R&D Expense: $71.4M (+100.0%); SG&A: $30.7M (+59.1%); Operating Loss: ($33.6M) (-128.6%); Net Loss: ($40.4M) (-142.1%); Loss Per Share: ($1.41) (-145.6%); Quick Assets: $197.8M (-2.5%).
    • No guidance given.
    | Mon, Feb. 29, 10:05 AM
  • Mon, Feb. 29, 8:04 AM
    • NewLink Genetics (NASDAQ:NLNK): Q4 EPS of -$0.75 beats by $0.17.
    • Revenue of $6.06M (+83.6% Y/Y) beats by $1.17M.
    • Shares +4.95% PM.
    • Press Release
    | Mon, Feb. 29, 8:04 AM
  • Nov. 3, 2015, 9:41 AM
    • NewLink Genetics (NLNK -0.5%) Q3 results: Revenues: $14.2M (+407.1%); R&D Expense: $22.5M (+106.4%); SG&A: $7.4M (+51.0%); Operating Loss: ($15.7M) (-20.8%); Net Loss: ($15.9M) (-183.9%); Loss Per Share: ($0.55) (-175.0%); Quick Assets: $200.4M (-1.2%).
    • 2015 Guidance: Cash and equivalents: >$160M.
    | Nov. 3, 2015, 9:41 AM
  • Nov. 3, 2015, 7:03 AM
    • NewLink Genetics (NASDAQ:NLNK): Q3 EPS of -$0.55 beats by $0.11.
    • Revenue of $14.21M (+407.5% Y/Y) beats by $7.45M.
    | Nov. 3, 2015, 7:03 AM
  • Jul. 31, 2015, 9:59 AM
    • NewLink Genetics (NLNK -0.7%) Q2 results: Revenues: $7.4M (+999%); R&D Expense: $16.1M (+147.7%); SG&A: $7.3M (+151.7%); Operating Loss: ($15.9M) (-74.7%); Net Loss: ($14.1M) (-53.3%); Loss Per Share: ($0.49) (-48.5%); Quick Assets: $207.6M (+2.4%).
    • 2015 Guidance: Cash and equivalents: >$160M,
    | Jul. 31, 2015, 9:59 AM | 1 Comment
  • Jul. 31, 2015, 7:01 AM
    • NewLink Genetics (NASDAQ:NLNK): Q2 EPS of -$0.49 beats by $0.21.
    • Revenue of $7.45M (+3447.6% Y/Y) beats by $3.13M.
    | Jul. 31, 2015, 7:01 AM
  • May 5, 2015, 11:12 AM
    • NewLink Genetics (NLNK +3.5%) Q1 results: Revenues: $39.2M (+999%); R&D Expense: $18M (+181.3%); SG&A: $8.4M (+154.5%); Operating Income: $12.8M (+237.6%); Net Income: $11.2M (+221.7%); EPS: $0.35 (+206.1%); Quick Assets: $214.4M (+5.7%).
    • 2015 Guidance: Cash & cash equivalents: ~160M.
    | May 5, 2015, 11:12 AM
  • May 5, 2015, 7:13 AM
    • NewLink Genetics (NASDAQ:NLNK): Q1 EPS of $0.35 beats by $0.94.
    • Revenue of $39.2M vs. $0.34M prior year beats by $36.88M.
    | May 5, 2015, 7:13 AM
  • Feb. 26, 2015, 7:16 AM
    • NewLink Genetics (NASDAQ:NLNK): Q4 EPS of $4.05 beats by $4.73.
    • Grant Revenue of $3.29M (+1034.5% Y/Y) beats by $0.31M.
    | Feb. 26, 2015, 7:16 AM
  • Nov. 6, 2014, 7:21 AM
    • NewLink Genetics (NASDAQ:NLNK): Q3 EPS of -$0.20 beats by $0.20.
    • Revenue of $2.8M (+976.9% Y/Y) beats by $2.49M.
    • Shares -0.65% PM.
    | Nov. 6, 2014, 7:21 AM
  • Oct. 27, 2014, 12:16 PM
    • NewLink Genetics (NLNK -0.6%) will report Q3 results on November 6 before the open. The conference call will begin at 8:30 am ET.
    • Consensus view is a loss of ($0.40) on revenues of $310K.
    | Oct. 27, 2014, 12:16 PM
  • Aug. 5, 2014, 8:05 AM
    • NewLink Genetics Corp. (NASDAQ:NLNK) Q2 results: Grant Revenue: $212K (-8.6%); Operating Expenses: $9.3M (+27.9%); Operating Loss: ($9.1M) (-29.6%); Net Loss: ($9.2M) (-29.6%); Loss Per Share: ($0.33) (-17.9%); Quick Assets: $77.1M (+25.4%).
    • No guidance given.
    | Aug. 5, 2014, 8:05 AM
Company Description
NewLink Genetics Corp. is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. Its portfolio includes biologic and small molecule immunotherapy product candidates... More
Sector: Healthcare
Industry: Biotechnology
Country: United States